AUS
NZ
UK
CA
USA
IND
Healthcare
Starpharma, Genentech Partner on DEP Cancer Therapies in ASX 200
September 22, 2025 04:25 PM AEST| By SamStarpharma (ASX:SPL) partners with Genentech to develop innovative DEP-based cancer therapies, highlighting opportunities in oncology and strengthening presence in the ASX 200 landscape.
EVE Health (ASX:EVE) Drives Innovation in Women’s Health with Dyspro Launch
September 22, 2025 11:52 AM AEST| By SamEVE Health (ASX:EVE) launches Dyspro, a cannabinoid-based gummy for menstrual pain, partnering with TeleDocs Clinic for nationwide distribution in Australia.
CSL Shares: Exploring Healthcare Strength Within the ASX 200
September 19, 2025 02:29 AM AEST| By SamCSL (ASX:CSL) showcases resilience in healthcare, offering stable revenue, ethical appeal, and global growth opportunities. Positioned within the ASX 200, it remains a cornerstone of long-term market strength.
Hearing Health Matters: How ASX 200 Innovation Shapes Lives
September 18, 2025 03:06 PM AEST| By SamGlobal news links untreated hearing loss to broader health issues. ASX-listed companies like Cochlear and Audeara are providing innovative tech solutions that are integrated into everyday devices.
Proteomics International Gains ISO 15189, Boosts ASX 200 Outlook
September 18, 2025 03:05 PM AEST| By SamProteomics International (ASX:PIQ) achieves ISO 15189 certification, strengthening its precision diagnostics portfolio and advancing PromarkerEso’s potential in transforming early cancer detection and global healthcare standards.
Unlocking the Value of ResMed CDI (ASX:RMD) Shares in 2025
September 17, 2025 05:35 PM AEST| By SamExplore an in-depth analysis of ResMed CDI (ASX:RMD) shares, their financial health, revenue trends, and role within the ASX 200 for 2025 investors.
4DMedical Ltd’s Strategic Quotation of New Securities on ASX 200
September 17, 2025 02:44 PM AEST| By Sam4DMedical Ltd (ASX:4DX) strengthens its market presence by quoting new securities on ASX, showcasing innovation in respiratory imaging and highlighting healthcare’s growing role in Australia’s evolving stock market landscape.
Nyrada’s Xolatryp Shows Breakthrough Potential in Brain and Heart Injury
September 16, 2025 07:50 PM AEST| By SamNyrada (ASX:NYR) advances its drug candidate Xolatryp, showing mitochondrial stabilisation in brain and heart injury, reinforcing biotech innovation within the dynamic ASX stock market.
CSL Expands Innovation Pathway with Dutch Partnership: ASX 200 Spotlight on Biotech Growth
September 16, 2025 03:06 PM AEST| By SamCSL (ASX:CSL), Orthocell (ASX:OCC), and Nyrada (ASX:NYR) drive biotech innovation on the ASX through global partnerships, advanced therapies, and medical devices, strengthening Australia’s healthcare sector and global research impact.
Mystate Limited’s New Securities Quotation
September 16, 2025 01:57 PM AEST| By SamMystate Limited (ASX:MYS) announces quotation of new securities under a dividend plan, strengthening liquidity, deepening shareholder engagement, and highlighting evolving capital management practices within the Australian Securities Exchange landsca...
CSL Limited (ASX:CSL) Accelerates Blood Coagulation Treatment Development
September 16, 2025 01:08 PM AEST| By SamCSL Limited (ASX:CSL) partners with VarmX to develop blood coagulation therapy, enhancing its ASX 200 healthcare portfolio, advancing clinical trials, and driving global patient-centric innovation.
CSL (ASX:CSL) Advances Innovative Blood Treatment: Key Developments Shaping ASX 200 Insights
September 16, 2025 11:22 AM AEST| By SamCSL (ASX:CSL) partners with VarmX to develop innovative blood therapy, reinforcing its ASX 200 presence and demonstrating leadership in global hematology, plasma treatments, and specialized patient care solutions.
Nova Eye Medical Expands ASX Presence: Exploring Market Momentum
September 15, 2025 02:33 PM AEST| By SamNova Eye Medical (ASX:EYE) enhances its ASX presence by quoting new securities, aligning employee incentives with innovation goals, and reinforcing stakeholder engagement in the evolving Australian stock market landscape.
Pro Medicus Hits Two-Month Low: What It Means for the Healthcare Sector and the ASX 200
September 15, 2025 02:17 PM AEST| By SamPro Medicus (ASX:PME) fell to a two-month low, reflecting broader healthcare weakness across the ASX. Sector trends, commodities, and technology highlight shifting dynamics in the Australian share market.
EVE Health (ASX:EVE) Expands Women’s Health Pipeline with New Scientific Advisory Board
September 15, 2025 12:09 PM AEST| By SamEVE Health Group (ASX:EVE) bolsters women’s health research with Dr Fiona Cousins on its Scientific Advisory Board, shaping future innovations in reproductive care.
ASX 200 Watch: Can PolyNovo’s Momentum Sustain in the Healthcare Sector?
September 12, 2025 04:41 PM AEST| By SamHighlights,PolyNovo shows renewed strength in recent trading sessions,Elevated valuation raises questions on future growth expectations,Healthcare innovation driving investor focus on performance,The,ASX 200,has often been a stage where healthcare in...
A Shifting Story for Nanosonics
September 11, 2025 07:12 PM AEST| By SamHighlights,Nanosonics faces market pressure despite earnings growth,Shareholder sentiment shaped by fundamentals and outlook,Broader ASX dynamics influence investor confidence,Nanosonics (ASX:NAN), a medical technology company best known for its infe...
Doctor Care Anywhere (ASX:DOC)
September 11, 2025 06:36 PM AEST| By SamHighlights,Doctor Care Anywhere (ASX:DOC) faces scrutiny despite strong share movement,Company valuation lags peers in healthcare services space,Future revenue outlook raises critical questions,The,ASX stock market,continues to generate headlines as...
Cleo Diagnostics & the Cash Runway Question: What Investors Should Know ASX 200
September 11, 2025 06:29 PM AEST| By SamHighlights,Cleo Diagnostics’ position under focus amid cash runway discussions,Biotech firms balance growth ambition with funding challenges,Broader insights for investors across the ASX stock market,The,ASX stock market,is home to companies ranging...
Who Owns Ansell (ASX:ANN)? Exploring Institutional Power in the ASX 200 Landscape
September 11, 2025 06:11 PM AEST| By SamHighlights,Ansell’s ownership is dominated by institutional investors,Broader market dynamics influence decision-making power,Public and insider stakes shape long-term governance,The role of institutional ownership in shaping corporate direction is i...
Advertise your brand on Kalkine Media